DrugPatentWatch Database Preview
Drugs in Development Information for Mapracorat
Development status for investigational drug Mapracorat: Sponsors, patents, clinical trial progress
Mapracorat is an investigational drug.
There have been 12 clinical trials for Mapracorat.
The most recent clinical trial was a Phase 3 trial, which was initiated on February 1st 2011.
The most common disease conditions in clinical trials are Inflammation, Cataract, and Eczema. The leading clinical trial sponsors are Bausch & Lomb Incorporated, Bayer, and [disabled in preview].
There are three US patents protecting this investigational drug and fifty-seven international patents.
Summary for Mapracorat
| US Patents | 3 |
| International Patents | 57 |
| US Patent Applications | 10 |
| WIPO Patent Applications | 2 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 3 (2011-02-01) |
| Vendors | 12 |
Recent Clinical Trials for Mapracorat
| Title | Sponsor | Phase |
|---|---|---|
| 1404003_OpenPsori.PlaqueTest to Eval.Eff.of Diff.Comp. to Mapracorat | Bayer | Phase 1 |
| Corneal Endothelial Cell Density Changes, When Mapracorat Ophthalmic Suspension 3%, is Administered for 14 Days | Bausch & Lomb Incorporated | Phase 1 |
| Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery | Bausch & Lomb Incorporated | Phase 3 |
Clinical Trial Summary for Mapracorat
Top disease conditions for Mapracorat
Top clinical trial sponsors for Mapracorat
US Patents for Mapracorat
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Mapracorat | Start Trial | 5-substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents | Schering AG (Berlin, DE) | Start Trial |
| Mapracorat | Start Trial | Pharmaceutical composition for topical application of poorly soluble compounds | Intendis GmbH (Berlin, DE) | Start Trial |
| Mapracorat | Start Trial | Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma | Northwestern University (Evanston, IL) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Mapracorat
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Mapracorat | Argentina | 051767 | 2024-11-12 | Start Trial |
| Mapracorat | Australia | 2005303926 | 2024-11-12 | Start Trial |
| Mapracorat | Brazil | PI0517797 | 2024-11-12 | Start Trial |
| Mapracorat | Canada | 2586689 | 2024-11-12 | Start Trial |
| Mapracorat | China | 101124220 | 2024-11-12 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
